Recombinant Yersinia pestis bv. Antiqua Lipoprotein signal peptidase (lspA)

What is Lipoprotein signal peptidase (lspA) in Yersinia pestis bv. Antiqua?

Lipoprotein signal peptidase (lspA) in Yersinia pestis bv. Antiqua is a crucial enzyme (EC 3.4.23.36) responsible for processing prolipoproteins by cleaving signal peptides from substrate lipoproteins during their maturation. This membrane-embedded protease specifically recognizes and cleaves the signal peptide after lipid modification of the conserved cysteine residue in the lipobox motif. In Yersinia pestis, proper processing of lipoproteins by lspA contributes to bacterial membrane integrity, virulence factor delivery, and potentially immune evasion mechanisms .

How does lspA contribute to the pathogenicity of Yersinia pestis?

LspA contributes to Y. pestis pathogenicity through several mechanisms:

• Membrane integrity maintenance: By processing lipoproteins that maintain outer membrane structure, lspA indirectly contributes to serum resistance, which is crucial for Y. pestis survival in host blood and tissues .

• Lipoprotein maturation: LspA processes lipoproteins that may be involved in immune evasion, such as those that interact with host complement components. Proper processing of lipoproteins like Ail contributes to the bacterium's ability to resist complement-mediated lysis .

• LPS processing and structure: Although indirect, lspA's role in processing membrane proteins can affect LPS structure, which is a major pathogenicity factor that contributes to Y. pestis virulence and immune evasion .

• Temperature-dependent pathogenicity: The function of processed lipoproteins may be affected by temperature, contributing to the bacterium's ability to transition between flea vectors (26°C) and mammalian hosts (37°C), influencing virulence expression in different environments .

What methodologies are recommended for expressing and purifying recombinant Y. pestis lspA?

Expression system recommendations:

Purification methodology:

• Membrane fraction isolation: Lyse cells by sonication or French press in buffer containing 20 mM Tris-HCl pH 8.0, 150 mM NaCl, protease inhibitors.

• Solubilization: Extract membrane proteins using detergents such as n-dodecyl-β-D-maltoside (DDM) or n-octyl-β-D-glucopyranoside (OG) at 1-2% concentration.

• Affinity purification: Using His-tag or other fusion tags, purify on appropriate resin with detergent-containing buffers.

• Size exclusion chromatography: Further purify and assess oligomeric state using appropriate columns.

• Storage: Store in Tris-based buffer with 50% glycerol at -20°C for extended stability .

How does lspA processing affect lipopolysaccharide (LPS) structure and function in Y. pestis?

LspA does not directly modify LPS but affects LPS structure and function through multiple indirect mechanisms:

• Lipoprotein-LPS interactions: LspA processes lipoproteins that may interact with and stabilize LPS in the outer membrane. Proper LPS organization contributes to Y. pestis serum resistance and immune evasion .

• LPS biosynthetic enzyme processing: Some enzymes involved in LPS modification are lipoproteins that require lspA for proper maturation. Defects in lspA could potentially affect LPS biosynthesis pathway enzymes.

• Temperature-dependent modifications: Y. pestis LPS structure varies based on temperature. At 37°C (mammalian host), Y. pestis produces LPS forms with specific modifications to the core oligosaccharide and lipid A. LspA-processed lipoproteins may be involved in these temperature-responsive modifications .

• Immune recognition effects: LPS from Y. pestis contains a core oligosaccharide bound to lipid A without an O-antigen polysaccharide chain, distinguishing it from LPS of other Yersinia species. This structure, potentially influenced by lspA-processed proteins, affects host immune recognition and bacterial virulence .

What role might lspA inhibition play in developing novel antimicrobial strategies against Y. pestis?

LspA inhibition offers promising antimicrobial potential through several mechanisms:

• Disruption of membrane integrity: Inhibiting lspA would prevent proper processing of multiple lipoproteins, potentially compromising membrane structure and function.

• Attenuation of virulence: Unprocessed lipoproteins may disrupt virulence factor secretion and function, reducing pathogenicity.

• Increased susceptibility to host defenses: Y. pestis with impaired lspA function would likely show reduced resistance to complement-mediated killing and other innate immune mechanisms .

• Synergistic therapy potential: LspA inhibitors could be combined with conventional antibiotics to enhance efficacy, particularly against antibiotic-resistant strains.

Experimental approaches for lspA inhibitor development:

How does the function of lspA relate to Y. pestis immune evasion mechanisms?

LspA plays an integral role in Y. pestis immune evasion through processing of several crucial lipoproteins:

• Ail processing: LspA is required for proper maturation of Ail, a key lipoprotein that contributes significantly to serum resistance. Y. pestis strains deficient in Ail are extremely sensitive to complement, indicating its critical role in evading this innate immune defense mechanism .

• Complement resistance: Y. pestis is resistant to complement-mediated lysis at both 26°C and 37°C, unlike enteropathogenic yersiniae. This resistance depends partly on properly processed lipoproteins, suggesting lspA's importance in maintaining this immune evasion mechanism .

• LPS structure modifications: LspA's indirect effects on LPS structure influence how Y. pestis interacts with host immune components. Temperature-dependent variations in LPS structure, potentially influenced by lspA-processed proteins, affect recognition by host pattern recognition receptors .

• Innate immunity modulation: Properly processed lipoproteins may help Y. pestis evade both insect-vector and mammal-host innate immunity factors, facilitating survival in both environments .

What experimental approaches are most effective for studying lspA function in Y. pestis?

Recommended experimental approaches:

For all experimental approaches studying Y. pestis lspA, appropriate biosafety measures must be implemented as Y. pestis is a Tier 1 Select Agent requiring BSL-3 containment. Using attenuated strains like KIM10(pCD1Ap) (Pgm−, pPCP1−) allows for safer handling while still providing valuable insights into lspA function .

How can recombinant lspA be used in vaccine development against Y. pestis?

Recombinant Y. pestis lspA has potential applications in vaccine development through several strategies:

• Subunit vaccine component: Purified recombinant lspA could be included in subunit vaccine formulations, potentially eliciting antibodies that interfere with lipoprotein processing.

• Live attenuated vaccine engineering: Strains with modified lspA activity could be developed as live attenuated vaccines with reduced virulence while maintaining immunogenicity. This approach could build upon existing attenuated strains like the YPS19(pCD1Ap) strain, which already shows promising protection against bubonic and pneumonic plague .

• Adjuvant development: Understanding how lspA-processed lipoproteins and LPS interact with the immune system could inform adjuvant design for plague vaccines.

Immunization route considerations:

Intramuscular (i.m.) administration with attenuated Y. pestis strains has been shown to afford significant protection against both bubonic and pneumonic plague compared to subcutaneous (s.c.) administration. The i.m. route induces balanced Th1 and Th2 responses, while s.c. administration stimulates Th2-biased responses, suggesting that route optimization is critical for effective immunity .

What are the temperature-dependent variations in lspA expression and how do they impact Y. pestis virulence?

Y. pestis demonstrates remarkable temperature-dependent variations in virulence factor expression as it transitions between flea vectors (26°C) and mammalian hosts (37°C). LspA function appears to be integrated within this temperature-responsive system:

• Expression patterns: While specific lspA expression data is limited, Y. pestis shows temperature-dependent regulation of multiple membrane components, including LPS structural modifications.

• Lipid A processing: Y. pestis modifies its lipid A structure in response to temperature, with tetra-acylated forms predominating at 37°C and hexa-acylated forms at lower temperatures. LspA-processed proteins may be involved in this temperature-dependent lipid A remodeling .

• Immune recognition consequences: The temperature-dependent LPS modifications affect recognition by host Toll-like receptors, with the 37°C form (found in mammals) generally being less stimulatory to the immune system, facilitating immune evasion .

• Vaccine implications: Understanding the temperature-dependence of lspA function could inform the development of temperature-controlled expression systems for attenuated vaccine strains. The YPS19(pCD1Ap) strain, which synthesizes mainly hexa-acylated lipid A (resembling the lower-temperature form), shows reduced virulence while maintaining immunogenicity .

How does Y. pestis bv. Antiqua lspA compare to lspA in other bacterial pathogens?

Y. pestis bv. Antiqua lspA shares significant homology with lspA from other bacterial species, but with important distinctions:

• Within Yersinia genus: There is 98-100% homology in proteins participating in key cellular processes (including lspA) within the Yersinia genus, reflecting their close evolutionary relationships .

• Compared to other Enterobacteriaceae: Y. pestis lspA shows moderate to high homology with lspA from other Enterobacteriaceae, but with specific sequence differences that might reflect adaptation to the plague bacterium's unique lifestyle.

• Functional conservation: The catalytic mechanism of lspA is highly conserved across bacterial species, reflecting the essential nature of lipoprotein processing.

• Substrate specificity variations: Different bacterial species may show variations in lspA substrate specificity and regulation, potentially contributing to pathogen-specific virulence mechanisms.

What are the key methodological considerations for performing structure-function studies on Y. pestis lspA?

Structure-function studies of Y. pestis lspA require careful methodological planning:

• Structural analysis approaches:

  • X-ray crystallography: Challenging due to membrane protein nature; requires detergent optimization

  • Cryo-EM: Increasingly valuable for membrane protein structure determination

  • NMR spectroscopy: Useful for dynamic regions and ligand interactions

  • Computational modeling: Based on homology with known structures

• Mutagenesis strategy:

  • Generate a panel of point mutations in catalytic residues and substrate-binding regions

  • Create chimeric proteins with lspA regions from other species to identify determinants of specificity

  • Express mutant proteins in lspA-deficient backgrounds to assess functional complementation

• Activity assays:

  • Develop fluorogenic peptide substrates based on native Y. pestis lipoprotein signal sequences

  • Establish cell-based assays measuring processing of reporter lipoproteins

  • Compare activity across temperature ranges relevant to Y. pestis lifecycle (20-37°C)

• Biosafety considerations:

  • Perform structure-function work in attenuated Y. pestis strains lacking key virulence factors

  • Consider using heterologous expression systems for initial characterization

How can recombinant Y. pestis lspA be utilized to identify novel antimicrobial targets?

Recombinant Y. pestis lspA offers multiple avenues for antimicrobial target discovery:

• High-throughput screening platform: Purified recombinant lspA can serve as a target for screening chemical libraries to identify inhibitors with potential antimicrobial activity.

• Structure-guided inhibitor design: Structural insights from recombinant lspA can guide the rational design of inhibitors targeting specific catalytic or binding sites.

• Substrate profiling: Using recombinant lspA to identify its complete substrate profile in Y. pestis could reveal additional lipoproteins that might serve as antimicrobial targets.

• Cross-species inhibition potential: Comparative studies between Y. pestis lspA and homologs from other pathogens could identify broadly acting inhibitors with potential against multiple bacterial species.

• Combination therapy exploration: Identifying synergistic interactions between lspA inhibitors and conventional antibiotics could lead to more effective treatment strategies, particularly important given concerns about antimicrobial resistance.

What strategies can optimize expression and stabilization of recombinant Y. pestis lspA for structural studies?

Optimizing expression and stabilization of recombinant Y. pestis lspA requires addressing several key challenges:

• Expression optimization:

  • Codon optimization for the expression host

  • Testing multiple fusion tags (His, MBP, SUMO) to identify optimal solubility and expression

  • Screening expression conditions (temperature, inducer concentration, duration)

  • Evaluating specialized expression systems for membrane proteins (C43(DE3), Lemo21(DE3))

• Membrane protein stabilization:

  • Systematic detergent screening (DDM, LMNG, GDN) for optimal extraction and stability

  • Incorporation into nanodiscs or lipid cubic phase for structural studies

  • Addition of specific lipids that might enhance stability

  • Use of thermostabilizing mutations based on computational prediction

• Storage and handling:

  • Store in Tris-based buffer with 50% glycerol at -20°C

  • Avoid repeated freeze-thaw cycles

  • Consider flash-freezing aliquots in liquid nitrogen

  • Test stabilizing additives (glycerol, specific lipids, cholesterol hemisuccinate)

• Quality assessment:

  • Size-exclusion chromatography to verify monodispersity

  • Thermal stability assays (differential scanning fluorimetry)

  • Activity assays to confirm functional integrity